Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.
Gunderson LL, Sargent DJ, Tepper JE, O'Connell MJ, Allmer C, Smalley SR, Martenson JA, Haller DG, Mayer RJ, Rich TA, Ajani JA, Macdonald JS, Goldberg RM. Gunderson LL, et al. Among authors: allmer c. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):386-96. doi: 10.1016/s0360-3016(02)02945-0. Int J Radiat Oncol Biol Phys. 2002. PMID: 12243812 Clinical Trial.
A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1).
Sloan JA, Bonner JA, Hillman SL, Allmer C, Shanahan TG, Brooks BJ, Marks RS, Vargas-Chanes D, Jett JR. Sloan JA, et al. Among authors: allmer c. Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):371-81. doi: 10.1016/s0360-3016(01)01819-3. Int J Radiat Oncol Biol Phys. 2002. PMID: 11872282 Clinical Trial.
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, Ajani JA, MacDonald JS, Willett CG, Goldberg RM. Gunderson LL, et al. Among authors: allmer c. J Clin Oncol. 2004 May 15;22(10):1785-96. doi: 10.1200/JCO.2004.08.173. Epub 2004 Apr 5. J Clin Oncol. 2004. PMID: 15067027
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
Wang Y, Farooq U, Link BK, Larson MC, King RL, Maurer MJ, Allmer C, Hefazi M, Thompson CA, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Ansell SM, Cerhan JR, Nowakowski GS. Wang Y, et al. Among authors: allmer c. J Clin Oncol. 2019 Jul 20;37(21):1819-1827. doi: 10.1200/JCO.19.00014. Epub 2019 Jun 6. J Clin Oncol. 2019. PMID: 31170029 Free PMC article.
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR. Maurer MJ, et al. Among authors: allmer c. J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18. J Clin Oncol. 2014. PMID: 24550425 Free PMC article. Clinical Trial.
77 results